Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer: The pathogenesis of bone destruction

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 735-740

  Kusumoto, Hiroki ^a   Haraguchi, Masaru ^a   Nozuka, Yoko ^b   Oda, Yoshinao ^b   Tsuneyoshi, Masazumi ^b   Iguchi, Haruo ^a,c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Bone destruction; Bone marrow invasion; Gastric cancer; Receptor activator of NF B ligand

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BONE; BONE MARROW; BONE MARROW CANCER; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TIME;

ADULT; AGED; BONE AND BONES; BONE MARROW; BONE MARROW NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND; STOMACH NEOPLASMS; TIME FACTORS;

EID: 39049175053     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.735     Document Type: Article

References (19)

1. Pasquini E, Gianni L, Aitini E, et al: Acute disseminated intravascular coagulation syndrome in cancer patients. Oncology 52: 505-508, 1995.
2. Crivellari D, Carbone A, Sigon R, et al: Gastric cancer with bone marrow invasion at presentation: case-report and review of the literature. Tumori 81: 74-76, 1995.
3. Noda N, Sano T, Shirao K, et al: A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval. Jpn J Clin Oncol 26: 472-475, 1996. (Pubitemid 126471809)
4. Hofbauer LC, Neubauer A and Heufelder AE: Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92: 460-470, 2001. (Pubitemid 32735180)
5. Kitazawa S and Kitazawa R: RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198: 228-236, 2002. (Pubitemid 35243881)
6. Oda Y, Takahira T, Kawaguchi K, et al: Alterations of cell cycle regulators in myxofibrosarcoma with special emphasis on their prognostic implications. Human Pathol 34: 1035-1042, 2003. (Pubitemid 37315256)
7. Morimatsu M, Shirouzu K, Irie K, et al: Gross and microscopic characteristics of stomach cancer with microangiopathic hemolytic anemia and/or disseminated intravascular coagulopathy. Acta Pathol Jpn 35: 809-822, 1985. (Pubitemid 15013391)
8. Yoshida M, Ohtsu A, Boku N, et al: Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 34: 654-659, 2004. (Pubitemid 41615277)
9. Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91: 1191-1200, 2001.
10. Carano A, Teitelbaum SL, Konsek JD, et al: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85: 456-461, 1990. (Pubitemid 20070052)
11. Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487, 1995.
12. Shipman CM, Croucher PI, Russell RG, et al: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297, 1998. (Pubitemid 28551102)
13. Senaratne SG, Pirianov G, Mansi JL, et al: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
14. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001. (Pubitemid 32685845)
15. Sezer O, Heider U, Jakob C, et al: Human bone marrow myeloma cells express RANKL. J Clin Oncol 20: 353-354, 2002.
16. Farrugia AN, Atkins GJ, To LB, et al: Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445, 2003. (Pubitemid 37139862)
17. Nosaka K, Miyamoto T, Sakai T, et al: Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99: 634-640, 2002. (Pubitemid 34533102)
18. Chikatsu N, Takeuchi Y, Tamura Y, et al: Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267: 632-637, 2000. (Pubitemid 30076850)
19. Alipov GK, Ito M, Nakashima M, et al: Expression of parathyroid hormone related peptide (PTHrP) in gastric tumours. J Pathol 182: 174-179, 1997. (Pubitemid 27287838)